Document is current
Any future updates will be listed below
-
Authors
Nägele, Felix
Pölzl, Leo
Graber, Michael
Hirsch, Jakob
Mayr, Agnes
Pamminger, Mathias
Troger, Felix
Theurl, Markus
Schreinlechner, Michael
Sappler, Nikolay
Dorfmüller, Christian
Mitrovic, Martina
Ulmer, Hanno
Grimm, Michael
Gollmann-Tepeköylü, Can
Holfeld, Johannes http://orcid.org/0000-0001-6623-0595
-
Funding
Funding for this research was provided by:
Heart Regeneration Technologies
National Heart, Lung, and Blood Institute
VASCage
- License Information
-
More Information
Article History
Received: 14 July 2022
Accepted: 12 November 2022
First Online: 9 December 2022
Declarations
:
: Prior to the study start, the study protocol and/or other appropriate documents were approved by the Ethics Committee of the Medical University of Innsbruck and competent authorities. IRB Number: 1118/2018. Written, informed consent to participate will be obtained from all participants.
: All participants will sign informed consent prior to study participation. Model consent form can be provided on request. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results.
: AM, CGT, FN FT, MGra, HU, JHi, LP, MM, MP, MT, MS, and NS declare they have no competing interests.JHo, CD and MGri are shareholders of Heart Regeneration Technologies GmbH, an Innsbruck Medical University spin-off aiming to promote cardiac shockwave therapy (ExternalRef removed).
